Luk H. Vandenberghe, PhD, is the Grousbeck Family Associate Professor in Gene Therapy at Mass Eye and Ear and Harvard Medical School, Director of the Grousbeck Gene Therapy Center, and an Associate Member of the Broad Institute of Harvard and MIT in Boston, MA, USA. He received a degree in cellular and genetic engineering from the University of Leuven, Belgium and subsequent training in several translational gene therapy laboratories at the University of Pennsylvania. His previous work led to the discovery of novel AAV serotypes such as AAV9, novel insights into AAV structure-function, and vector immunobiology. His laboratory aims to gain a deeper understanding of mechanisms of gene transfer, to develop technologies to overcome hurdles to gene therapy clinical applications, and to translate specific gene therapy programs in vision, hearing, and other fields. Dr. Vandenberghe previously co-founded several biotechs and a non-profit called Odylia Therapeutics aimed at catalyzing translation for gene therapies within the challenging field of ultra-rare disorders. Dr. Vandenberghe has over a dozen licensed patents and more than 80 peer reviewed publications in the field of gene therapy.
« Go Back